The Burrill Report


The Burrill Report (December 2, 2013): Why Pharma Companies Are Looking More Like Biotechs (.MP3,14.27 Mb)

Over the last 20 years, biologics have made up an increasingly critical portion of Big Pharma’s pipeline. Last year, biotech products accounted for 71 percent of the revenue generated by the world’s 10 top selling drugs, according to a new report from the Tufts Center for the Study of Drug Development. We spoke to Ronald Evens, adjunct faculty at the University of the Pacific and biotechnology consultant with the center about the report, why Big Pharma has become so reliant on biologics, and whether there’s a meaningful distinction today between pharma and biotech companies.


November 28, 2013
http://www.burrillreport.com/article-why_pharma_companies_are_looking_more_like_biotechs_.html